John Elfar

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, John Elfar sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 3 currently recruiting early-phase tilt upper quartile by trial count

John Elfar: 3 sponsored US clinical trials, 3 recruiting.

John Elfar sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Wounds and Injuries, with 2 trials.

Upper-quartile sponsor footprint

John Elfar sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

3 total, page 1 of 1

RECRUITING Phase 2

4-Aminopyridine to Treat Skin Burns

NCT06596434
RECRUITING Phase 2

4-aminopyridine for Skin Wound Healing

NCT06333171
RECRUITING Phase 2

4-aminopyridine Treatment for Nerve Injury

NCT03701581

Phase Distribution

PhaseTrial count
Phase 2 3

Therapeutic Areas

Wounds and Injuries 2
Second Degree Burn 1
Nerve Injury 1
Burns 1
Wounds 1
Wound of Skin 1
Wound Heal 1
Prostate Cancer 1

What is open in the John Elfar pipeline

3 recruiting of 3 indexed (100% open).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Wounds and Injuries (2 trials), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

John Elfar: open-pipeline peers nationwide

Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

John Elfar sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share John Elfar10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
John Elfar sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

John Elfar sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this John Elfar page

3 registered trials is a research-attention snapshot, not an endorsement of John Elfar or any single study.

  • 3 of John Elfar's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Wounds and Injuries is the condition John Elfar studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Wounds and Injuries trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

John Elfar pipeline card: 3 registered trials from official public datasets.Report a data error.